CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

Q2 2025 Earnings Call Transcript July 22, 2025 Sap Se beats earnings expectations. Reported EPS is $1.7, expectations were $1 ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

The enterprise suite introduces four key AI agents – finance, payments, accounting and project management – each designed to ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance Published on July 11, 2025 at 4:00 pm by Ramish Cheema in News << Prev Page 10 of 13 ...

In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed a JPMorgan note suggesting that its clients expected President Trump to be more accommodating when it came to market ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Senator Maggie Hassan is investigating GSK's controversial asthma inhaler switch, alleging the move put the medication out of reach for some patients.